Importantly, the phase 2 clinical trial assessed the efficacy and safety of AK112, a humanized IgG1 anti-VEGF × PD-1 BsAb, in combination with chemotherapy in advanced NSCLC [99]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.